231 related articles for article (PubMed ID: 9585800)
1. Pharmacokinetic interactions between two human immunodeficiency virus protease inhibitors, ritonavir and saquinavir.
Hsu A; Granneman GR; Cao G; Carothers L; el-Shourbagy T; Baroldi P; Erdman K; Brown F; Sun E; Leonard JM
Clin Pharmacol Ther; 1998 Apr; 63(4):453-64. PubMed ID: 9585800
[TBL] [Abstract][Full Text] [Related]
2. Saquinavir 500 mg film-coated tablets demonstrate bioequivalence to saquinavir 200 mg hard capsules when boosted with twice-daily ritonavir in healthy volunteers.
Bittner B; Riek M; Holmes B; Grange S
Antivir Ther; 2005; 10(7):803-10. PubMed ID: 16312177
[TBL] [Abstract][Full Text] [Related]
3. Single daily doses of saquinavir achieve HIV-inhibitory concentrations when combined with baby-dose ritonavir.
Kurowski M; Müller M; Donath F; Mrozikiewicz M; Möcklinghoff C
Eur J Med Res; 1999 Mar; 4(3):101-4. PubMed ID: 10085276
[TBL] [Abstract][Full Text] [Related]
4. Steady-state pharmacokinetics of a double-boosting regimen of saquinavir soft gel plus lopinavir plus minidose ritonavir in human immunodeficiency virus-infected adults.
Ribera E; Lopez RM; Diaz M; Pou L; Ruiz L; Falcó V; Crespo M; Azuaje C; Ruiz I; Ocaña I; Clotet B; Pahissa A
Antimicrob Agents Chemother; 2004 Nov; 48(11):4256-62. PubMed ID: 15504850
[TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetic interaction between rifampicin and the once-daily combination of saquinavir and low-dose ritonavir in HIV-infected patients with tuberculosis.
Ribera E; Azuaje C; Lopez RM; Domingo P; Curran A; Feijoo M; Pou L; Sánchez P; Sambeat MA; Colomer J; Lopez-Colomes JL; Crespo M; Falcó V; Ocaña I; Pahissa A
J Antimicrob Chemother; 2007 Apr; 59(4):690-7. PubMed ID: 17307771
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetic interaction between ritonavir and clarithromycin.
Ouellet D; Hsu A; Granneman GR; Carlson G; Cavanaugh J; Guenther H; Leonard JM
Clin Pharmacol Ther; 1998 Oct; 64(4):355-62. PubMed ID: 9797791
[TBL] [Abstract][Full Text] [Related]
7. Reducing the boosting dose of ritonavir does not affect saquinavir plasma concentrations in HIV-1-infected individuals.
van der Lugt J; Gorowara M; Avihingsanon A; Burger D; Ananworanich J; Sringam K; Kerr S; Wit F; Lange J; Ruxrungtham K
AIDS; 2009 Jun; 23(9):1176-9. PubMed ID: 19451794
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetics of saquinavir hard gel/ritonavir (1000/100 mg twice daily) when administered with tenofovir diproxil fumarate in HIV-1-infected subjects.
Boffito M; Back D; Stainsby-Tron M; Hill A; Di Perri G; Moyle G; Nelson M; Tomkins J; Gazzard B; Pozniak A
Br J Clin Pharmacol; 2005 Jan; 59(1):38-42. PubMed ID: 15606438
[TBL] [Abstract][Full Text] [Related]
9. Effect of food and ranitidine on saquinavir pharmacokinetics and gastric pH in healthy volunteers.
Kakuda TN; Falcon RW
Pharmacotherapy; 2006 Aug; 26(8):1060-8. PubMed ID: 16863482
[TBL] [Abstract][Full Text] [Related]
10. Effect of omeprazole on the pharmacokinetics of saquinavir-500 mg formulation with ritonavir in healthy male and female volunteers.
Winston A; Back D; Fletcher C; Robinson L; Unsworth J; Tolowinska I; Schutz M; Pozniak AL; Gazzard B; Boffito M
AIDS; 2006 Jun; 20(10):1401-6. PubMed ID: 16791014
[TBL] [Abstract][Full Text] [Related]
11. A pharmacokinetic study of intermittent rifabutin dosing with a combination of ritonavir and saquinavir in patients infected with human immunodeficiency virus.
Gallicano K; Khaliq Y; Carignan G; Tseng A; Walmsley S; Cameron DW
Clin Pharmacol Ther; 2001 Aug; 70(2):149-58. PubMed ID: 11503009
[TBL] [Abstract][Full Text] [Related]
12. Exploratory study comparing the metabolic toxicities of a lopinavir/ritonavir plus saquinavir dual protease inhibitor regimen versus a lopinavir/ritonavir plus zidovudine/lamivudine nucleoside regimen.
Cameron DW; Becker S; King MS; da Silva B; Klein C; Tokimoto D; Foit C; Calhoun D; Bernstein B; Hanna GJ
J Antimicrob Chemother; 2007 May; 59(5):957-63. PubMed ID: 17350990
[TBL] [Abstract][Full Text] [Related]
13. The effect of ABCB1 polymorphism on the pharmacokinetics of saquinavir alone and in combination with ritonavir.
la Porte CJ; Li Y; Béïque L; Foster BC; Chauhan B; Garber GE; Cameron DW; van Heeswijk RP
Clin Pharmacol Ther; 2007 Oct; 82(4):389-95. PubMed ID: 17361121
[TBL] [Abstract][Full Text] [Related]
14. Saquinavir, nelfinavir and M8 pharmacokinetics following combined saquinavir, ritonavir and nelfinavir administration.
Stocker H; Herzmann C; Breske A; Kruse G; Berger M; Schulbin H; Hill A; Steinmüller J; Becker M; Arastéh K; Kurowski M
J Antimicrob Chemother; 2007 Mar; 59(3):560-4. PubMed ID: 17255144
[TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetic characterization of a human immunodeficiency virus protease inhibitor, saquinavir, during ethanol intake in rats.
Shibata N; Kageyama M; Kishida T; Kimura K; Yoshikawa Y; Kuwahara T; Toh J; Shirasaka T; Takada K
Biopharm Drug Dispos; 2003 Nov; 24(8):335-44. PubMed ID: 14595702
[TBL] [Abstract][Full Text] [Related]
16. Effect of saquinavir/ritonavir (1000/100 mg bid) on the pharmacokinetics of methadone in opiate-dependent HIV-negative patients on stable methadone maintenance therapy.
Jamois C; Smith P; Morrison R; Riek M; Patel A; Schmitt C; Morcos PN; Zhang X
Addict Biol; 2009 Jul; 14(3):321-7. PubMed ID: 19523046
[TBL] [Abstract][Full Text] [Related]
17. Effect of simultaneous versus staggered dosing on pharmacokinetic interactions of protease inhibitors.
Washington CB; Flexner C; Sheiner LB; Rosenkranz SL; Segal Y; Aberg JA; Blaschke TF;
Clin Pharmacol Ther; 2003 May; 73(5):406-16. PubMed ID: 12732841
[TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetic interaction between darunavir and saquinavir in HIV-negative volunteers.
Sekar VJ; Lefebvre E; Mariën K; De Pauw M; Vangeneugden T; Hoetelmans RM
Ther Drug Monit; 2007 Dec; 29(6):795-801. PubMed ID: 18043478
[TBL] [Abstract][Full Text] [Related]
19. A pharmacokinetic model for evaluating the impact of hepatic and intestinal first-pass loss of saquinavir in the rat.
Lledó-García R; Nácher A; Casabó VG; Merino-Sanjuán M
Drug Metab Dispos; 2011 Feb; 39(2):294-301. PubMed ID: 20978105
[TBL] [Abstract][Full Text] [Related]
20. Effect of ketoconazole on ritonavir and saquinavir concentrations in plasma and cerebrospinal fluid from patients infected with human immunodeficiency virus.
Khaliq Y; Gallicano K; Venance S; Kravcik S; Cameron DW
Clin Pharmacol Ther; 2000 Dec; 68(6):637-46. PubMed ID: 11180024
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
